ZNF24

Summary

ZNF24 (zinc finger protein 24, HGNC:13032) is a protein-coding gene on chromosome 18q12.2, encoding Zinc finger protein 24 (P17028). Transcription factor required for myelination of differentiated oligodendrocytes.

Enables DNA-binding transcription activator activity, RNA polymerase II-specific; identical protein binding activity; and sequence-specific DNA binding activity. Involved in negative regulation of DNA-templated transcription and positive regulation of transcription by RNA polymerase II. Located in nucleoplasm.

Source: NCBI Gene 7572 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 33 total
• MANE Select transcript: NM_006965

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13032
Approved symbol	ZNF24
Name	zinc finger protein 24
Location	18q12.2
Locus type	gene with protein product
Status	Approved
Aliases	ZSCAN3, Zfp191, KOX17
Ensembl gene	ENSG00000172466
Ensembl biotype	protein_coding
OMIM	194534
Entrez	7572

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 16 protein_coding

ENST00000261332, ENST00000399061, ENST00000589539, ENST00000589881, ENST00000590140, ENST00000593130, ENST00000876552, ENST00000876553, ENST00000876554, ENST00000876555, ENST00000876556, ENST00000876557, ENST00000876558, ENST00000931765, ENST00000931766, ENST00000954189

RefSeq mRNA: 3 — MANE Select: NM_006965 NM_001308123, NM_001375815, NM_006965

CCDS: CCDS11912, CCDS77175

Canonical transcript exons

ENST00000261332 — 4 exons

Exon	Start	End
ENSE00000668338	35339829	35339976
ENSE00001256469	35344360	35344420
ENSE00001387215	35340231	35340733
ENSE00002860589	35332227	35337770

Expression profiles

Bgee: expression breadth ubiquitous, 299 present calls, max score 97.45.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.7551 / max 473.6693, expressed in 1801 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
171644	29.7551	1801

Top tissues by expression

299 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
medial globus pallidus	UBERON:0002477	97.45	gold quality
globus pallidus	UBERON:0001875	97.15	gold quality
corpus callosum	UBERON:0002336	97.10	gold quality
inferior vagus X ganglion	UBERON:0005363	96.85	gold quality
olfactory bulb	UBERON:0002264	96.74	silver quality
pylorus	UBERON:0001166	96.18	gold quality
cardia of stomach	UBERON:0001162	95.82	gold quality
nipple	UBERON:0002030	95.82	gold quality
cranial nerve II	UBERON:0000941	95.58	gold quality
subthalamic nucleus	UBERON:0001906	95.53	gold quality
buccal mucosa cell	CL:0002336	95.36	gold quality
mucosa of paranasal sinus	UBERON:0005030	95.09	gold quality
lateral globus pallidus	UBERON:0002476	94.96	gold quality
ventral tegmental area	UBERON:0002691	94.91	gold quality
medulla oblongata	UBERON:0001896	94.90	gold quality
calcaneal tendon	UBERON:0003701	94.76	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	94.71	gold quality
superior vestibular nucleus	UBERON:0007227	94.57	gold quality
pericardium	UBERON:0002407	94.50	gold quality
pons	UBERON:0000988	94.46	gold quality
mammary duct	UBERON:0001765	94.44	gold quality
ventricular zone	UBERON:0003053	94.35	gold quality
superficial temporal artery	UBERON:0001614	94.20	gold quality
dorsal plus ventral thalamus	UBERON:0001897	94.03	gold quality
amniotic fluid	UBERON:0000173	93.93	gold quality
substantia nigra pars reticulata	UBERON:0001966	93.88	gold quality
epithelium of mammary gland	UBERON:0003244	93.88	gold quality
vena cava	UBERON:0004087	93.74	gold quality
ganglionic eminence	UBERON:0004023	93.62	gold quality
superior surface of tongue	UBERON:0007371	93.62	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	11.64
E-GEOD-99795	no	142.22

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

5 targets.

Target	Regulation
CCND1	Activation
CTNNB1	Activation
MSLN	Unknown
PDGFRB	Repression
VEGFA	Repression

JASPAR motifs

Motif	Name	Family
MA1124.1	ZNF24	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:11532988

miRNA regulators (miRDB)

197 targeting ZNF24, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6758-5P	100.00	66.21	1470
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-6856-5P	100.00	65.47	1298
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-9-5P	100.00	72.28	2361
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4531	99.99	69.70	3181
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-8075	99.97	67.20	962
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478

Literature-anchored findings (GeneRIF, showing 13)

• Overexpression and purification of single zinc finger peptides of ZNF191 were performed. (PMID:17270462)
• ZNF191 is a pleiotropic factor that has a role in hematopoiesis, brain development, and tumor growth. (PMID:19463170)
• Data confirm ZNF191 as an essential factor acting for the promotion of the cell cycle and thus maintenance in the progenitor stage. (PMID:19544452)
• These data suggest that ZNF24 is involved in negative regulation of PDGFR-beta and may represent a novel repressor of PDGFR-beta transcription. (PMID:20510677)
• ZNF191 can directly bind to the CTNNB1 promoter and activate the expression of beta-catenin and its downstream target genes such as cyclin D1 in hepatoma cell lines. (PMID:22213192)
• ZNF24 may be implicated in transcriptional regulation of genes associated with oncogenesis via interaction with H2A.Z. (PMID:22678762)
• ZNF24 represses VEGF transcription through direct binding to an 11-bp fragment of the VEGF proximal promoter and that it functions as a negative regulator of tumor growth by inhibiting angiogenesis. (PMID:23212515)
• results suggest that consecutive ZF1-2 is critical for the regulation of ZNF24 nuclear localization and its transactivation function. (PMID:24224020)
• In vivo, knockdown of ZNF24 specifically in microvascular endothelial cells led to significantly decreased formation of functional vascular networks. (PMID:25550468)
• miR-940 promoted gastric cancer progression by directly downregulating ZNF24 expression. (PMID:26317898)
• Wnt8B, transcriptionally regulated by ZNF191, promotes cell proliferation of hepatocellular carcinoma via Wnt signaling. (PMID:33197287)
• ZNF191 alters DNA methylation and activates the PI3K-AKT pathway in hepatoma cells via transcriptional regulation of DNMT1. (PMID:35092191)
• Tumor-suppressive zinc finger protein 24 (ZNF24) sensitizes colorectal cancer cells to 5-fluorouracil by inhibiting the Wnt pathway and activating the p53 signaling. (PMID:37774763)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp24	ENSMUSG00000051469
rattus_norvegicus	Zfp24	ENSRNOG00000075202

Paralogs (30): ZNF263 (ENSG00000006194), ZNF213 (ENSG00000085644), ZNF500 (ENSG00000103199), ZKSCAN1 (ENSG00000106261), ZNF205 (ENSG00000122386), ZSCAN9 (ENSG00000137185), PGBD1 (ENSG00000137338), ZNF215 (ENSG00000149054), ZSCAN12 (ENSG00000158691), ZNF394 (ENSG00000160908), ZNF75A (ENSG00000162086), ZSCAN21 (ENSG00000166529), ZNF232 (ENSG00000167840), ZNF449 (ENSG00000173275), ZSCAN4 (ENSG00000180532), ZSCAN22 (ENSG00000182318), ZNF75D (ENSG00000186376), ZNF396 (ENSG00000186496), ZNF397 (ENSG00000186812), ZSCAN30 (ENSG00000186814), ZKSCAN4 (ENSG00000187626), ZSCAN23 (ENSG00000187987), ZKSCAN3 (ENSG00000189298), ZSCAN16 (ENSG00000196812), ZSCAN25 (ENSG00000197037), ZSCAN26 (ENSG00000197062), ZNF165 (ENSG00000197279), ZKSCAN8 (ENSG00000198315), ZSCAN31 (ENSG00000235109), ZNF853 (ENSG00000236609)

Protein

Protein identifiers

Zinc finger protein 24 — P17028 (reviewed: P17028)

Alternative names: Retinoic acid suppression protein A, Zinc finger and SCAN domain-containing protein 3, Zinc finger protein 191, Zinc finger protein KOX17

All UniProt accessions (4): P17028, K7EPL1, K7EPZ8, K7EQP8

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor required for myelination of differentiated oligodendrocytes. Required for the conversion of oligodendrocytes from the premyelinating to the myelinating state. In the developing central nervous system (CNS), involved in the maintenance in the progenitor stage by promoting the cell cycle. Specifically binds to the 5’-TCAT-3’ DNA sequence. Has transcription repressor activity in vitro.

Subcellular location. Nucleus.

Tissue specificity. Expressed in many tissues except in heart.

Post-translational modifications. Sumoylated.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
P17028-1	1	yes
P17028-2	2

RefSeq proteins (3): NP_001295052, NP_001362744, NP_008896* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003309	SCAN_dom	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR038269	SCAN_sf	Homologous_superfamily

Pfam: PF00096, PF02023

UniProt features (45 total): cross-link 10, helix 9, modified residue 5, strand 5, zinc finger region 4, splice variant 2, sequence variant 2, mutagenesis site 2, turn 2, chain 1, domain 1, sequence conflict 1, region of interest 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
3LHR	X-RAY DIFFRACTION	1.9
1X6E	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P17028-F1	66.50	0.21

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (15): 292, 335, 22, 27, 27, 147, 177, 236, 277, 286, 361, 367, 132, 142, 274

Mutagenesis-validated functional residues (2):

Position	Phenotype
286	partial cytoplasmic accumulation.
290	partial cytoplasmic accumulation.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 147 (showing top): BROWNE_HCMV_INFECTION_6HR_DN, chr18q12, WANG_LMO4_TARGETS_DN, MILI_PSEUDOPODIA_HAPTOTAXIS_UP, BLALOCK_ALZHEIMERS_DISEASE_UP, GOBP_ENSHEATHMENT_OF_NEURONS, E4F1_Q6, DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_UP, NAKAMURA_TUMOR_ZONE_PERIPHERAL_VS_CENTRAL_DN, FISCHER_DREAM_TARGETS, NOUZOVA_TRETINOIN_AND_H4_ACETYLATION, ZHANG_BREAST_CANCER_PROGENITORS_UP, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_DN, CETS1P54_01, RYTGCNWTGGNR_UNKNOWN

GO Biological Process (4): regulation of transcription by RNA polymerase II (GO:0006357), myelination (GO:0042552), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (10): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), zinc ion binding (GO:0008270), identical protein binding (GO:0042802), sequence-specific DNA binding (GO:0043565), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
transcription by RNA polymerase II	2
regulation of transcription by RNA polymerase II	2
axon ensheathment	1
DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
positive regulation of DNA-templated transcription	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
transition metal ion binding	1
protein binding	1
DNA binding	1
nucleic acid binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1230 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF24	MAPRE2	Q15555	775
ZNF24	CLOCK	O15516	595
ZNF24	RBFA	Q8N0V3	479
ZNF24	OLIG1	Q8TAK6	458
ZNF24	HBP1	O60381	446
ZNF24	MZF1	P28698	438
ZNF24	TCF24	Q7RTU0	436
ZNF24	ZNF202	O95125	433
ZNF24	ZSCAN1	Q8NBB4	432
ZNF24	SNX22	Q96L94	431
ZNF24	ZPR1	O75312	421
ZNF24	MYRF	Q9Y2G1	416
ZNF24	KCNH3	Q9ULD8	412
ZNF24	CC2D1A	Q6P1N0	410
ZNF24	BBX	Q8WY36	409

IntAct

326 interactions, top by confidence:

A	B	Type	Score
PGBD1	ZNF24	psi-mi:“MI:0915”(physical association)	0.900
ZNF24	PGBD1	psi-mi:“MI:0915”(physical association)	0.900
ZNF24	ZSCAN32	psi-mi:“MI:0915”(physical association)	0.880
ZSCAN32	ZNF24	psi-mi:“MI:0915”(physical association)	0.880
ZNF24	ZKSCAN4	psi-mi:“MI:0915”(physical association)	0.880
ZNF446	ZNF24	psi-mi:“MI:0915”(physical association)	0.850
ZNF24	SCAND1	psi-mi:“MI:0915”(physical association)	0.850
ZSCAN21	ZNF24	psi-mi:“MI:0915”(physical association)	0.830
ZNF24	ZSCAN21	psi-mi:“MI:0915”(physical association)	0.830
ZNF24	ZNF446	psi-mi:“MI:0915”(physical association)	0.810
ZNF446	ZNF24	psi-mi:“MI:0915”(physical association)	0.810

BioGRID (238): ZNF24 (Two-hybrid), ZNF24 (Two-hybrid), ZSCAN21 (Two-hybrid), DZIP3 (Two-hybrid), FAM115A (Two-hybrid), MID2 (Two-hybrid), ZSCAN32 (Two-hybrid), ZNF446 (Two-hybrid), PGBD1 (Two-hybrid), ZNF483 (Two-hybrid), ZNF396 (Two-hybrid), ZNF24 (Affinity Capture-MS), ZNF24 (Biochemical Activity), ZNF446 (Affinity Capture-MS), SCAND1 (Affinity Capture-MS)

ESM2 similar proteins: A1YEP8, A1YEQ3, A1YEV9, A1YFW2, A1YFW6, A1YG26, A1YG48, A1YG60, A1YGJ4, A2T6V8, A2T6W2, A2T712, A2T736, A2T7D7, A2T7F4, A2T7L7, A6QNZ0, O15535, P10073, P17028, P17029, P49910, Q07231, Q15776, Q16670, Q1LZ87, Q3MJ62, Q4KLI1, Q53GI3, Q5R670, Q5R741, Q5RAE6, Q5RJ54, Q6P9G9, Q86W11, Q8BGS3, Q8CF60, Q8NF99, Q91VN1, Q91VW9

Diamond homologs: A1YEP8, A1YEQ3, A1YEV9, A1YFW2, A1YFW6, A1YG26, A1YG48, A1YG60, A1YGJ4, A1YGK6, A2T6E3, A2T6V8, A2T6W2, A2T712, A2T736, A2T7D2, A2T7D7, A2T7F2, A2T7F4, A2T7L7, A2T812, A6QNZ0, A6QPT6, B2KFW1, O14709, O14771, O14978, O15535, O43309, O60304, O95125, P10073, P17022, P17028, P17029, P17040, P28698, P49910, P51815, P59923

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	29
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

827 predictions. Top by Δscore:

Variant	Effect	Δscore
18:35339824:CTCA:C	donor_loss	1.0000
18:35339826:CAC:C	donor_loss	1.0000
18:35339828:C:A	donor_loss	1.0000
18:35339828:CCA:C	donor_gain	1.0000
18:35339853:C:CA	donor_gain	1.0000
18:35339865:A:AC	donor_gain	1.0000
18:35339866:C:CC	donor_gain	1.0000
18:35339972:GAAAC:G	acceptor_gain	1.0000
18:35339973:AAAC:A	acceptor_gain	1.0000
18:35339974:AAC:A	acceptor_gain	1.0000
18:35339975:AC:A	acceptor_gain	1.0000
18:35339975:ACCTG:A	acceptor_loss	1.0000
18:35339976:CC:C	acceptor_gain	1.0000
18:35339977:C:CC	acceptor_gain	1.0000
18:35339978:T:G	acceptor_loss	1.0000
18:35344349:T:A	donor_gain	1.0000
18:35344371:T:TA	donor_gain	1.0000
18:35337768:CAT:C	acceptor_gain	0.9900
18:35337771:C:CC	acceptor_gain	0.9900
18:35339827:A:AC	donor_gain	0.9900
18:35339828:C:CC	donor_gain	0.9900
18:35339952:C:A	donor_gain	0.9900
18:35339984:C:CT	acceptor_gain	0.9900
18:35339985:A:T	acceptor_gain	0.9900
18:35340225:GCTCA:G	donor_loss	0.9900
18:35340226:CTCAC:C	donor_loss	0.9900
18:35340227:TCACC:T	donor_loss	0.9900
18:35340228:CACCG:C	donor_loss	0.9900
18:35340229:A:AC	donor_gain	0.9900
18:35340229:A:C	donor_loss	0.9900

AlphaMissense

2410 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
18:35337391:A:C	F316L	0.999
18:35337391:A:T	F316L	0.999
18:35337393:A:G	F316L	0.999
18:35337475:G:C	F288L	0.999
18:35337475:G:T	F288L	0.999
18:35337477:A:G	F288L	0.999
18:35337364:A:C	H325Q	0.997
18:35337364:A:T	H325Q	0.997
18:35337366:G:C	H325D	0.997
18:35337559:G:C	F260L	0.997
18:35337559:G:T	F260L	0.997
18:35337561:A:G	F260L	0.997
18:35337374:A:G	L322P	0.996
18:35337392:A:G	F316S	0.996
18:35337448:G:C	H297Q	0.996
18:35337448:G:T	H297Q	0.996
18:35337450:G:C	H297D	0.996
18:35337476:A:G	F288S	0.996
18:35337352:A:C	H329Q	0.995
18:35337352:A:T	H329Q	0.995
18:35337362:T:G	Q326P	0.995
18:35337366:G:T	H325N	0.995
18:35337446:T:G	Q298P	0.995
18:35340433:A:G	L73P	0.995
18:35337436:G:C	H301Q	0.994
18:35337436:G:T	H301Q	0.994
18:35337458:A:G	L294P	0.994
18:35337534:G:C	H269D	0.994
18:35337414:A:G	C309R	0.993
18:35337420:A:C	Y307D	0.993

dbSNP variants (sampled 300 via entrez): RS1000058747 (18:35342547 T>C), RS1000654799 (18:35333692 G>A,T), RS1000661020 (18:35343735 A>G), RS1000948362 (18:35343473 G>A), RS1001008754 (18:35343986 G>A), RS1001599139 (18:35344080 T>A), RS1001650216 (18:35343813 G>T), RS1001929786 (18:35345136 A>G), RS1001983969 (18:35344784 T>C), RS1002062080 (18:35344621 G>T), RS1002236590 (18:35332332 T>C), RS1002594003 (18:35342721 C>T), RS1002646435 (18:35342507 G>T), RS1002661315 (18:35346144 T>G), RS1002852347 (18:35338854 T>C,G)

Disease associations

OMIM: gene MIM:194534 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

44 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	5
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	4
Air Pollutants	affects cotreatment, increases abundance, increases oxidation, affects expression, decreases expression	3
Ozone	affects cotreatment, increases oxidation, increases abundance, affects expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
methylselenic acid	decreases expression	1
trichostatin A	affects expression	1
beta-lapachone	increases expression	1
manganese chloride	increases abundance, increases expression, affects cotreatment	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
pentabromodiphenyl ether	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
jinfukang	decreases expression	1
PCI 5002	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Acetaminophen	affects response to substance	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Cadmium	increases abundance, increases expression	1
Caffeine	increases phosphorylation	1
Coal	decreases expression, increases abundance	1
Doxorubicin	decreases expression	1

Cellosaurus cell lines

2 cell lines: 1 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_AW47	K562 eGFP-ZNF24	Cancer cell line	Female
CVCL_HD16	HEK293 eGFP-ZNF24	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.